March 23-26th 2021 :
Defymed is happy to announce its participation in the SFD (French diabetes society) virtual congress which will take place from March 23 to 26, 2021.
This event is particularly important for Defymed because it allows our company to meet important players in the field of diabetes at the French-speaking level.
This congress will offer various conferences and exchanges which will allow us to get in touch with various professionals in the sector. The SFD congress will highlight diabetes news in the fields of technological and therapeutic advances which will allow us to draw parallels with our MailPan® and ExOlin® devices.
Severine Sigrist, our Chief Executive Officer, will participate to the online conference. Severine will also give a talk on the symposium “ROUTES OF INSULIN ADMINISTRATION AND THE FIRST HEPATIC
PASS”. Our CEO will present Defymed’s pre-clinical data on diabetics and non-diabetics rat using ExOlin® device implanted in the Extraperitoneal space. Intraperitoneal insulin delivery has higher benefits than subcutaneous insulin administration but has limitations, including obstruction of the catheter used in delivery devices. To overcome these limitations Defymed’s prove safety and efficacy in preclinical model of an alternative approach involving a new delivery device, named ExOlin®, allowing diffuse release of insulin in the extraperitoneal site.
If you have any question on the importance of this routes to deliver insulin, or on the impact of insulin tolerance to improve the quality of life of patient, do not hesitate to connect you on the virual congress Wednesday march 24th between 10 and 11am. This conference will be in French.